CHMP recommends FIRMAGON* (degarelix) for Advanced PCa

[Guest guest]

Ferring Pharmaceuticals received notification that the CHMP, part of the European Medicines Agency (EMEA), has adopted a positive opinion and is recommending to grant a marketing authorization for FIRMAGON* (degarelix), a new GnRH receptor antagonist indicated for patients with advanced, hormone-dependent prostate cancer. In Phase III studies degarelix produced a significant reduction in levels of testosterone within three days in more than 96% of study patients. Testosterone plays a major role in the growth and spread of

prostate cancer cells. Click on below link for the full story:<http://www.medicalnewstoday.com/articles/133655.php>If you try to browse elsewhere within the above medical web site, you'll be requested to

register, which you can safely do.Patients are welcome and there's never any spam.